8th Apr 2014 10:43
LONDON (Alliance News) - Specialist medical technology company ANGLE PLC said Tuesday that it has taken steps to strengthen its intellectual property covering its Parsortix system.
The company has filed claims covering new applications for the Parsortix system, including harvesting blood cells for analysis and determining the size of cells. If the new patent applications are granted they will extend the intellectual property protection on the product until at least 2033, ANGLE said.
"Our intellectual property strategy is key to our business and this strengthening of our IP is an important commercial milestone," said Chief Executive Andrew Newland in a statement.
In March the company submitted an application to the United States Food and Drug Administration to authorise the sale of Parsortix as an in vitro diagnostic device in the US.
The product is currently used to capture circulating tumour cells from cancer patient blood for mutational analysis, using a simple blood test to capture the cancer cells for analysis.
Shares in ANGLE were trading up 0.5% at 95.00 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle